Haleon director acquires 242 shares
Haleon plc disclosed that its Senior Independent Non-Executive Director acquired 242 shares via dividend reinvestment on the London Stock Exchange.
Rhea-AI Filing Summary
Haleon plc (HLN) reported a small share transaction by a senior board member. Senior Independent Non-Executive Director Alan Stewart, classified as a Person Discharging Managerial Responsibilities, acquired 242 ordinary shares of Haleon on September 17, 2026 through a dividend reinvestment arrangement.
The shares were purchased at a price of £3.378619 per share on the London Stock Exchange. The disclosure is made in line with the requirements of the UK Market Abuse Regulation governing PDMR dealings in company securities.
Positive
- None.
Negative
- None.
Key Figures
Shares acquired: 242 shares
Acquisition price: £3.378619 per share
Transaction date: September 17, 2026
3 metrics
Shares acquired
242 shares
Ordinary shares acquired by Senior Independent Non-Executive Director via dividend reinvestment
Acquisition price
£3.378619 per share
Price paid for Haleon ordinary shares acquired on September 17, 2026
Transaction date
September 17, 2026
Date of PDMR acquisition of Haleon ordinary shares
Key Terms
Person Discharging Managerial Responsibilities, UK Market Abuse Regulation, dividend reinvestment
3 terms
Person Discharging Managerial Responsibilities regulatory
"notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by a Person Discharging Managerial Responsibilities"
A person discharging managerial responsibilities is an individual who holds a senior role with authority to make or influence a company’s strategic or operational decisions, such as executives, board members, or other top managers. Investors care because these people often have access to confidential information and their buying or selling of company shares must be disclosed—like a referee who knows the score before the crowd, their actions can signal important, non-public insights about a company's prospects.
UK Market Abuse Regulation regulatory
"in accordance with the requirements of The UK Market Abuse Regulation of Transactions"
dividend reinvestment financial
"Acquisition of Ordinary Shares as a result of dividend reinvestment"
Dividend reinvestment is when the money earned from a company's profit sharing, called dividends, is automatically used to buy more shares of that company instead of being received as cash. This process helps investors grow their holdings over time without extra effort, much like using earned interest to buy more of a savings account. It encourages long-term investment growth by continuously increasing the amount of shares owned.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Haleon (HLN) report in this 6-K?
Haleon reported that Senior Independent Non-Executive Director Alan Stewart acquired 242 ordinary shares in the company on September 17, 2026 through a dividend reinvestment transaction on the London Stock Exchange.
Who is the PDMR involved in the Haleon (HLN) transaction disclosed?
The Person Discharging Managerial Responsibilities involved is Alan Stewart, who serves as Haleon’s Senior Independent Non-Executive Director. He acquired 242 ordinary shares via dividend reinvestment on September 17, 2026.
On which market was the Haleon (HLN) PDMR transaction executed?
The PDMR transaction was executed on the London Stock Exchange (XLON), where 242 Haleon ordinary shares were acquired via dividend reinvestment at £3.378619 per share on September 17, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September
2026
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
18
September 2026 - “Director/PDMR
Shareholding”
|
99.1
Haleon
plc: Director/PDMR
Shareholding
18 September 2026: Haleon
plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces
notification and public disclosure in accordance with the
requirements of The UK Market Abuse Regulation of Transactions by a
Person Discharging Managerial Responsibilities
("PDMR").
On 18 September 2026, the Company received notification of the
following transaction as detailed below.
|
1
|
Details of the issuer, emission allowance market
participant
|
||||
|
a)
|
Name
|
Haleon plc
|
|||
|
b)
|
LEI
|
549300PSB3WWEODCUP19
|
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Senior Independent Non-Executive Director
|
|||
|
b)
|
Initial notification /Amendment
|
Initial Notification
|
|||
|
3
|
Details of the person discharging managerial responsibilities /
person closely associated ("PCA")
|
||||
|
a)
|
PDMR/PCA
|
PDMR
|
|||
|
b)
|
Name
|
Alan Stewart
|
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||||
|
a)
|
Description of Instrument
Identification code
|
Share
GB00BMX86B70
|
|||
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares as a result of dividend
reinvestment
|
|||
|
c)
|
Currency, Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
|
£3.378619
|
242
|
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|||
|
|
|
||||
|
- Aggregated volume
|
N/A
|
||||
|
|
|
||||
|
- Price
|
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
17 September 2026
|
|||
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|||
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused
on better everyday health. Our people, our brands, our research,
our investment and our innovation are aimed at improving the
everyday health of consumers. Our product portfolio spans six major
categories - Oral Health, Vitamins, Minerals and Supplements (VMS),
Pain Relief, Respiratory Health, Digestive Health and Therapeutic
Skin Health and Other. Our superior brands - such as
Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers
and are recommended by health professionals around the
world.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date:
September 18, 2026
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|